|
Activation of mitochondrial function and Hb expression in non-haematopoietic cells by an EPO inducer ameliorates ischaemic diseases in mice
|
|
Pei-Lun Hsu, Lin-Yea Horng, Kang-Yung Peng, Chia-Ling Wu, Hui-Ching Sung and Rong-Tsun Wu
|
|
British Journal of Pharmacology, 169: 1461, 2013.
|
|
|
|
This paper was chosen as key scientific article by Global Medical Discovery(Canada) in 2014.
|
|
|
|
During our manuscript submitting for publication, the reviewer commend:
The translational aspect of this study presented was to demonstrate that these changes induced by EH-201 have a potential therapeutic effect for ischemic diseases. Preclinical studies evaluating compounds with the unique mechanism that can potentially address ischemic diseases are very interesting and relevant because of the large unmet medical need. The most important and exciting aspect of this work is that EH-201 can be used as a therapeutic agent (instead of only a preventive agent) after established cisplatin-induced nephropathy or doxorubicin-induced cardiomyopathy. Most often, compounds that work to prevent injury in animal models fail at the clinical stage.
|
|
|